Sangro, BBSangroChan, S LS LChanKelley, R KR KKelleyLau, GGLauKudo, MMKudoSukeepaisarnjaroen, WWSukeepaisarnjaroenYarchoan, MMYarchoanDe Toni, E NE NDe ToniFuruse, JJFuruseKang, Y KY KKangGalle, P RP RGalleRimassa, LLRimassaHeurgué, AAHeurguéTam, V CV CTamVan Dao, TTVan DaoThungappa, S CS CThungappaBreder, VVBrederOstapenko, YYOstapenkoReig, MMReigMakowsky, MMMakowskyPaskow, M JM JPaskowGupta, CCGuptaKurland, J FJ FKurlandNegro, AANegroAbou-Alfa, G KG KAbou-AlfaANN-LII CHENG2024-03-292024-03-292024-02-1909237534https://scholars.lib.ntu.edu.tw/handle/123456789/641591In the phase III HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) versus sorafenib; durvalumab monotherapy was noninferior to sorafenib for OS. Results reported herein are from a 4-year updated OS analysis of HIMALAYA.endurvalumab; immune checkpoint inhibitor; overall survival; tremelimumab; unresectable hepatocellular carcinomajournal article10.1016/j.annonc.2024.02.005383828752-s2.0-85188011236https://api.elsevier.com/content/abstract/scopus_id/85188011236